Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203216 | 0.91 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13007239 | 0.83 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13061423 | 0.81 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3770289 | 0.79 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8203629 | 0.76 | HDAC6 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15906849 | 0.76 | HDAC3 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15906839 | 0.75 | HDAC6 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8203146 | 0.74 | HDAC6 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13007240 | 0.73 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8203133 | 0.72 | EPHX1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| EP-2077999-B1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-12-16 | — | — | US | disclosed |
| WO-2008053131-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | H1-2, HDAC1, H1-0 | HDAC3 13/4885HDAC4 10/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.